Metavention
Eden Prairie
About Metavention
Metavention develops new treatment that is intended to permanently disrupt the overactive nerves that cause high blood pressure and other metabolic diseases. They offer a renal denervation procedure that delivers radio frequency energy to targeted overactive sympathetic nerves using their IRF denervation system.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $65.0M
- Funding stage: Late Stage Venture
- Last round: Series C (Jan 2018)
- Website: metavention.com
- Phone: 16128148202
Industries & Categories
Biotechnology, Diabetes, Health Care
Social Profiles
Canonical: https://fsome.com/organization/metavention-95084 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.